🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being viewed as a "huge turning point" in the effort against superbug strains of the bacteria, according to health experts.

An International Challenge

Gonorrhoea infections are escalating worldwide, with estimates suggesting over 82 million infections per year. Notably increased rates are reported in the African continent and nations within the WHO's designated area, which encompasses China and Mongolia to New Zealand. Across England, cases have hit a record high, while rates across Europe in 2023 were triple the level compared to figures for 2014.

“The authorization of novel therapies for gonorrhoea is an significant and necessary advancement in the reality of rising global incidence, increasing antimicrobial resistance and the very limited therapeutic options currently available.”

Health officials are increasingly worried about the increase in drug-resistant strains. The global health body has designated it as a "priority pathogen". Recent surveillance showed that the effectiveness of primary antibiotics like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

A Pair of Novel Therapies Secure Authorization

Zoliflodacin, alternatively called Nuzolvence, was cleared by the US Food and Drug Administration in recent days for treating gonorrhoea. This disease can lead to significant complications, including infertility. Researchers believe that focused deployment of this new drug will help delay the emergence of superbugs.

Gepotidacin, created by the pharmaceutical company GlaxoSmithKline, was also approved in the same week. This drug, which is employed against urinary tract infections, was shown in trials to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin stemmed from a new, not-for-profit approach for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the drug firm Innoviva to develop it.

“This authorization marks a huge turning point in the management of multidrug-resistant gonorrhoea, which up to this point has been staying ahead of antibiotic development.”

Clinical Trial Outcomes and Global Access

According to findings detailed in a major medical journal, zoliflodacin eradicated the vast majority of uncomplicated infections. This puts it on an equal footing with the existing first-line therapy, which involves two antibiotics. The study included nearly 1,000 participants from several countries including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its development partnership, the non-profit has the authority to license and sell the drug in a wide range of low-income and middle-income countries.

Clinicians treating patients have voiced optimism. Having a single-dose, oral treatment like this is hailed as a "game-changer" for public health efforts. This is viewed as crucial to alleviate the strain of the disease for patients and to halt the transmission of highly drug-resistant gonorrhoea worldwide.